Significantly expand current emergency healthcare expenses and future budgets for potentially life-saving innovative drugs. At the end of the day, prices are numbers. Lives are not.
There’s a need for the policy responses to the economic front to correspond more closely to the public health front in terms of urgency and stringency.
Breakthrough cases and high infectivity rate of variants could make vaccination targets to be underestimated, and threaten NRP indicators towards recovery.
Moving on from regulatory incentive to focusing now on fiscal incentive (financial & tax) – for both “essential” and “non-essential” sectors and sub-sectors.